Clinical Trial Results:
Single-center, double-blind, randomized, placebo-controlled, 2-period/2-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fibrosis homozygous for the ΔF508 mutation
Summary
|
|
EudraCT number |
2006-002049-35 |
Trial protocol |
ES |
Global end of trial date |
22 Feb 2008
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
07 Nov 2019
|
First version publication date |
06 Aug 2015
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AC-056-201
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Idorsia Pharmaceuticals Ltd
|
||
Sponsor organisation address |
Hegenheimermattweg 91, Allschwil, Switzerland, 4123
|
||
Public contact |
Clinical Trials Disclosure Desk, Idorsia Pharmaceuticals Ltd, clinical-trials-disclosure@idorsia.com
|
||
Scientific contact |
Clinical Trials Disclosure Desk, Idorsia Pharmaceuticals Ltd, clinical-trials-disclosure@idorsia.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Feb 2009
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
22 Feb 2008
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Feb 2008
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate that miglustat restores the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients with cystic fibrosis homozygous for the ΔF508 mutation, as reflected in nasal potential difference (NPD)
|
||
Protection of trial subjects |
Prior to the start of the trial the study center consulted an Independent Ethics Committee (IEC), i.e., a review panel that was responsible for ensuring the protection of the rights, safety, and well-being of human patients involved in a clinical investigation. The sponsor ensured that the IEC consulted was adequately constituted to provide assurance of that protection, and maintained a list of committee members and their qualifications. The protocol and any material provided to the patient (such as a subject information sheet or description of the study used to obtain informed consent) were reviewed and approved by the appropriate IEC before the study was started.
This study was conducted in full conformance with the principles of the ‘Declaration of Helsinki’ and with the laws and regulations of the country in which the research was conducted.
Both Actelion and the investigator had the right to terminate the study at any time, and in such a case, were responsible for protecting the patients’ interests.
Written informed consent was obtained from each individual participating in the study prior to any study procedure and after adequate explanation of the aims, methods, objectives, and potential hazards of the study. It was made clear to each patient that he or she was completely free to refuse to enter the study, or to withdraw from it at any time for any reason. A description of any incentives to participate in the study was provided in the informed consent form.
|
||
Background therapy |
Miglustat or placebo was given on top of standard care. Restrictions were applied for other investigational drugs and/or therapies, e.g., gene therapy. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Nov 2007
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 3
|
||
Worldwide total number of subjects |
3
|
||
EEA total number of subjects |
3
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
3
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
One investigational center in Spain. The study was terminated prematurely after only 3 patients had participated in the study. One reason for premature study termination was low recruitment. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
Screening examinations were done within 3 weeks and 3 days prior to the first administration of study medication. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Baseline Period
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Double blind | ||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | ||||||||||
Blinding implementation details |
The investigator and study staff, the patients, monitors, and the sponsor staff remained blinded to the treatment until study closure. The investigational drug and its matching placebo were indistinguishable and all patient kits were packaged in the same way.
|
||||||||||
Arms
|
|||||||||||
Arm title
|
Miglustat 200 mg t.i.d. | ||||||||||
Arm description |
Miglustat 200 mg t.i.d. | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Miglustat 200 mg t.i.d.
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
Miglustat 200 mg t.i.d. capsules, oral use
|
||||||||||
|
|||||||||||
Period 2
|
|||||||||||
Period 2 title |
Period 1
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Double blind | ||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | ||||||||||
Blinding implementation details |
The investigator and study staff, the patients, monitors, and the sponsor staff remained blinded to the treatment until study closure. The investigational drug and its matching placebo were indistinguishable and all patient kits were packaged in the same way.
|
||||||||||
Arms
|
|||||||||||
Arm title
|
Miglustat 200 mg t.i.d. | ||||||||||
Arm description |
Miglustat 200 mg t.i.d. for 7 days | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Miglustat 200 mg t.i.d.
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
Miglustat 200 mg t.i.d. capsules, oral use
|
||||||||||
|
|||||||||||
Period 3
|
|||||||||||
Period 3 title |
Period 2
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Double blind | ||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | ||||||||||
Blinding implementation details |
The investigator and study staff, the patients, monitors, and the sponsor staff remained blinded to the treatment until study closure. The investigational drug and its matching placebo were indistinguishable and all patient kits were packaged in the same way.
|
||||||||||
Arms
|
|||||||||||
Arm title
|
Placebo | ||||||||||
Arm description |
Placebo 200 mg t.i.d. | ||||||||||
Arm type |
Placebo | ||||||||||
Investigational medicinal product name |
Placebo 200 mg t.i.d.
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
Matching placebo 200 mg t.i.d. capsules, oral use
|
||||||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline Period
|
|||||||||||||||||||||||||||||||||
Reporting group description |
Not applicable | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||
Subject analysis set title |
All-treated set
|
|||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||
Subject analysis set description |
This analysis set includes all randomized patients who received study drug.
|
|||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Miglustat 200 mg t.i.d.
|
||
Reporting group description |
Miglustat 200 mg t.i.d. | ||
Reporting group title |
Miglustat 200 mg t.i.d.
|
||
Reporting group description |
Miglustat 200 mg t.i.d. for 7 days | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo 200 mg t.i.d. | ||
Subject analysis set title |
All-treated set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
This analysis set includes all randomized patients who received study drug.
|
|
||||||||||
End point title |
Not applicable [1] | |||||||||
End point description |
Not applicable
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Not applicable
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Not applicable. |
||||||||||
|
||||||||||
Notes [2] - Not applicable [3] - Not applicable |
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
Adverse events information
|
|||||||||||||||
Timeframe for reporting adverse events |
Adverse events from start of Period 1 (Day 1) to end of study (Day 28, Period 2). Serious adverse events from Day -21 until Day 1 (if related to study-mandated procedures) and from Day 1 to Day 56 (Follow up).
|
||||||||||||||
Assessment type |
Systematic | ||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||
Dictionary version |
9.0
|
||||||||||||||
Reporting groups
|
|||||||||||||||
Reporting group title |
Overall Period
|
||||||||||||||
Reporting group description |
Period 1 and 2 | ||||||||||||||
|
|||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |